Bruker (BRKR) Corporation announced it has commenced a public offering, subject to market and other conditions, of $600M of mandatory convertible preferred stock, Series A. Bruker intends to use the net proceeds from this offering to strengthen the balance sheet and enhance strategic flexibility by repaying (i) its term loan due December 2026 in full, (ii) outstanding borrowings under its 2024 amended and restated revolving credit agreement in full, and (iii) a portion of its term loan due March 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Scion takes new position in Lululemon, reduces stake in Estee Lauder
- Bruker signs $27M in explosives, chemical trace detection solutions contracts
- Bruker Corporation Faces Challenges Amid Revenue Decline
- Bruker price target lowered to $40 from $48 at Stifel
- Bruker Corporation Reports Q2 2025 Financial Results